0      0

Breakfast Activity/Non-CE-Accredited Satellite Symposium <br>Janssen Oncology invites you to learn more about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody<br>Janssen: Pharmaceutical Companies of Johnson & Johnson </br> <br><i>Seating available on first-come, first-served basis</br></i>

‐ Nov 10, 2023 7:45am

Donna Catamaro, ANP-BC, OCN, CCRC

You must be logged in and own this session in order to post comments.